The specter of generic rivalry has consistently loomed above copyright’s blockbuster drug, Viagra, triggering questions about the prospects of similar pharmaceutical ventures. While early years saw substantial gains, the intellectual property lapse has created the door for cheaper substitutes, potentially diminishing earnings and posing a real d… Read More